Cellectis : Individual Shareholder Meeting

Regulatory News :

Cellectis (Paris:ALCLS) :

Event Details:

Date: October 23, 2014
Time: 6:00 to 8:30PM
Location: Cellectis – 11 rue Watt – 75013 Paris

André Choulika, PhD, Chairman and Chief Executive Officer of Cellectis, Mathieu Simon, MD, Executive Vice President and Thierry Moulin, Chief Financial Officer, will present to the Company's individual shareholders perspectives on developing immunotherapies based on engineering CART allogeneic (UCART) lymphocytes.

Feel free to send your questions ahead of the meeting at media@cellectis.com.

Please RSVP with:

Cellectis / Jennifer Moore jennifer.moore@cellectis.com Phone: 01 81 69 16 00

Upon invitation – limited seats available

About Cellectis
Cellectis is a biopharmaceutical company focused on oncology. The company’s mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Cellectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN™, meganucleases and the state-of-the-art electroporation technology PulseAgile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Cellectis adoptive cancer immunotherapy for chronic and acute leukemias is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Cellectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com.